Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of APL-2 (pegcetacoplan) in Paroxysmal Nocturnal Hemoglobinuria
2018-004220-11Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- May 2019
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in paroxysmal nocturnal hemoglobinuria (PNH) comparing Pegcetacoplan arm with Standard of care arm (excluding complement inhibitors) (2 arms). Primary endpoint: Hemoglobin stabilization through Week 26. Started May 2019; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2018-004220-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004220-11.